Abstract:Risheng Xu, Michael E Xie, Christopher M Jackson Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA Correspondence: Christopher M Jackson Johns Hopkins Hospital 1800 Orleans St., Phipps 102, Baltimore, MD, 21287, USA Email Trigeminal neuralgia (TN) has been described in the literature as one of the most debilitating presentations of orofacial pain. This review summarizes over 150 years of collective clinical experience in the medical and surgical treatment of TN. Fundamentally, TN remains a clinical diagnosis that must be distinguished from other types of trigeminal neuropathic pain and/or facial pain associated with other neuralgias or headache syndromes. What is increasingly clear is that there is no catch-all medical or surgical intervention that is effective for all patients with trigeminal neuralgia, likely reflective of the fact that TN is likely a heterogenous group of disorders that jointly manifests in facial pain. The first-line treatment for TN remains anticonvulsant medical therapy. Patients who fail this have a range of surgical options available to them. In general, microvascular decompression is a safe and effective procedure with immediate and durable outcomes. Patients who are unable to tolerate general anesthesia or whose medical comorbidities preclude a suboccipital craniectomy may benefit from percutaneous methodologies including glycerol or radiofrequency ablation, or both. For patients with bleeding diathesis due to blood thinning medications who are ineligible for invasive procedures, or for those who are unwilling to undergo open surgical procedures, radiosurgery may be an excellent option—provided the patient understands that maximum pain relief will take on the order of months to achieve. Finally, peripheral neurectomies continue to provide an inexpensive and resource-sparing alternative to pain relief for patients in locations with limited economic and medical resources. Ultimately, elucidation of the molecular mechanisms underlying trigeminal neuralgia will pave the way for novel, more effective and less invasive therapies. Keywords: trigeminal neuralgia, facial pain, glycerol, radiofrequency, microvascular decompression, partial sensory rhizotomy Trigeminal neuralgia (TN) has been described in the literature as one of the most debilitating presentations of orofacial pain. 1 The earliest descriptions of TN date back into the seventeenth century with prominent physicians such as Johannes Fehr and Elias Schmidt, secretaries of the Imperial Leopoldina Academy of the Natural Sciences, and famous philosopher John Locke. 2 Nicholas Andre first linked TN pain to the nervous system in the mid-1700s when he described the condition as a convulsive disorder thought to originate from a nerve under distress. The term tic douloureux, which Andre used to describe the clinical entity, was used to capture the facial distortions and grimaces associated with the sharp, stabbing pain that characterized the condition. In 1773, John Fothergill offered a clinical description of trigeminal neuralgia: "The affection seems to be peculiar to persons advancing in years, and to women more than to men. The pain comes suddenly and is excruciating; it lasts but a short time, perhaps a quarter or half a minute, and then goes off; it returns at irregular intervals, sometimes in half an hour, sometimes there are two or three repetitions in a few minutes. Eating will bring it on some persons. Talking, or the least motion of the muscles of the face affects the others; the gentlest touch of a handkerchief will sometimes bring on the pain, while a strong pressure on the part has no effect". Although Fothergill offered an accurate clinical description of TN, he thought TN was a manifestation of some type of cancer, and proffered the term Fothergill's disorder to capture the clinical entity. 3 It was not until 1820 when Dr Charles Bell localized the facial pain symptoms that patients experienced to the trigeminal ganglion that a true anatomical basis of disease was established. 4 As a specific entity of facial pain, TN today is recognized by a variety of classification systems: TN thus refers to a category of disorders affecting one or more branches of the trigeminal nerve that present with neuropathic pain. 11,12 They are classified as follows: Otherwise known as typical TN, type I TN is characterized by unilateral, severe, brief, paroxysms of sharp painful attacks in the distribution of one or more branches of the trigeminal nerve. These attacks are often described as electrical and shock-like. The pain is maximal at onset, lasts several seconds, and is triggered by nonpainful stimuli. Typical triggers include cold air, brushing teeth, chewing, or talking. Trigger zones are areas in the distribution of the affe -Abstract Truncated-

Role of common and rare genetic variants in the aetiology of trigeminal neuralgia

Genome-wide association study reveals genetic risk factors for trigeminal neuralgia

Genomic Validation in the UK Biobank Cohort Suggests a Role of C8B and MFG-E8 in the Pathogenesis of Trigeminal Neuralgia

Exome sequencing implicates impaired GABA signaling and neuronal ion 1 transport in trigeminal neuralgia

Familial trigeminal neuralgia – a systematic clinical study with a genomic screen of the neuronal electrogenisome

Molecular mechanisms of trigeminal neuralgia: A systematic review

The Molecular Basis and Pathophysiology of Trigeminal Neuralgia

Electrophysiological and computational analysis of Cav3.2 channel variants associated with familial trigeminal neuralgia

Mechanistic contribution of CaV3.2 calcium channels to trigeminal neuralgia pathophysiology not clarified

Ca V 3.2 calcium channels contribute to trigeminal neuralgia

Trigeminal Neuralgia: Current Approaches and Emerging Interventions

Identification of Candidate Genes Associated with Postherpetic Neuralgia Susceptibility

A Novel Pathophysiological Mechanism Contributing to Trigeminal Neuralgia

The role of biomarkers in drug-resistant trigeminal neuralgia: a prospective study in patients submitted to surgical treatment

Trigeminal neuralgia and its comorbidities: a nationwide disease trajectory study

Therapeutic Efficacy of Botulinum Toxin in Trigeminal Neuralgia

Trigeminal neuralgia – diagnosis and treatment

Exonic mutations in SCN9A (NaV1.7) are found in a minority of patients with erythromelalgia

Retrospective Analysis of Clinical Feature in Trigeminal Neuralgia

A Retrospective Analysis of Medical Management Strategies for Trigeminal Neuralgia: An Institutional Review

Systemic Inflammatory Regulators Are Associated with Two Common Types of Neuropathic Pain: A Bidirectional Mendelian Randomization Study